---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-032185"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:37:57.286044+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M

## Summary
- Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.
- Operating loss $2.6M vs loss of $284K; adjusted EBITDA loss $1.7M vs positive $450K.
- Cash $5.0M, no debt; net cash used in ops $4.0M for the quarter.
- CEO cites biotech downturn; bookings improving, expects revenue growth in H2.
- Drug discovery subsidiary Corellia AI progressing; company seeking capital to accelerate programs.

## SEC filing metadata
- accession: 0001628280-23-032185
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/csbr-20230913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-032185
- JSON: https://secwatch.observer/filing/0001628280-23-032185.json
- Plain text: https://secwatch.observer/filing/0001628280-23-032185.txt

## Key facts
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
  - Period: first quarter of fiscal 2024 ended July 31, 2023
  - Result: reported results
  source text: Total revenue for the first quarter of fiscal 2024 was $12.6 million compared to $13.7 million for the same period last year, a decrease of 8.6%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
  - Period: first quarter of fiscal 2024 ended July 31, 2023
  - Result: reported results
  source text: For the first quarter of fiscal 2024, Champions reported a loss from operations of $2.6 million , including $423,000 in stock-based compensation and $445,000 in depreciation and amortization expenses, compared to a loss from operations of $284,000 , inclusive of $206,000 in stock-based compensation and $528,000 in depreciation and amortization expenses, in the first quarter of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
  - Period: first quarter of fiscal 2024 ended July 31, 2023
  - Result: reported results
  source text: Excluding stock-based compensation, depreciation and amortization expenses, Champions reported an adjusted EBITDA loss of $1.7 million for the first quarter of fiscal 2024 compared to adjusted EBITDA of $450,000 in the first quarter of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.